Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis (EALIPPCA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by Ministry of Science and Technology of the People´s Republic of China.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Peking University First Hospital
Information provided by:
Ministry of Science and Technology of the People´s Republic of China
ClinicalTrials.gov Identifier:
NCT00723320
First received: July 21, 2008
Last updated: August 22, 2008
Last verified: July 2008
  Purpose

The purpose of this study is to determine whether atorvastatin, aggressive lifestyle intervention, and their interaction are effective in delaying the progress of pre-clinical atherosclerosis.


Condition Intervention
Atherosclerosis
Drug: Atorvastatin
Behavioral: Aggressive lifestyle intervention

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: Effect of Atorvastatin and Lifestyle Intervention on Progression of Carotid Intima-Media Thickness in Chinese People Without Manifest Atherosclerotic Disease

Resource links provided by NLM:


Further study details as provided by Ministry of Science and Technology of the People´s Republic of China:

Primary Outcome Measures:
  • The progress of CIMT [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The progress of ABI [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • The progress of PWV [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Occurrence of atherosclerotic disease [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 1200
Study Start Date: February 2008
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: P+N
placebo without lifestyle intervention
Experimental: D+N
Atorvastatin 10mg/d
Drug: Atorvastatin
atorvastatin 10mg/d
Experimental: P+A
lifestyle intervention without Atorvastatin
Behavioral: Aggressive lifestyle intervention
aggressive lifestyle intervention
Experimental: D+A
lifestyle intervention and Atorvastatin 10mg/d
Drug: Atorvastatin
atorvastatin 10mg/d
Behavioral: Aggressive lifestyle intervention
aggressive lifestyle intervention

Detailed Description:

Primary prevention of atherosclerotic disease remains a big challenge. Currently, it is not clear how to treat those subjects with evidence of pre-clinical atherosclerosis but without obvious conventional risk factors. This randomized, placebo controlled, double blind study is to evaluate the effect of Atorvastatin 10 mg daily, therapeutic lifestyle change, and their combination, on the progression of CIMT in those with higher baseline CIMT value but are not belong to 'high risk' category, according to the conventional risk factors.

  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CIMT is not less than 0.9 mm
  • without Clinical diagnosis of atherosclerotic disease
  • without Diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00723320

Contacts
Contact: Jianping Li 86-10-66551122 ext 5262

Locations
China, Beijing
Peking University First Hospital Recruiting
Beijing, Beijing, China, 100034
Contact       lijianping@medmail.com.cn   
Sponsors and Collaborators
Ministry of Science and Technology of the People´s Republic of China
Peking University First Hospital
Investigators
Principal Investigator: Jianping Li Peking University First Hospital
  More Information

No publications provided

Responsible Party: Yong Huo, Peking University First Hospital
ClinicalTrials.gov Identifier: NCT00723320     History of Changes
Other Study ID Numbers: 2006BAI01A02-03
Study First Received: July 21, 2008
Last Updated: August 22, 2008
Health Authority: China: Ministry of Health

Keywords provided by Ministry of Science and Technology of the People´s Republic of China:
Atherosclerosis
Atorvastatin
Therapeutic lifestyle change
CIMT
ABI
PWV

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases
Atorvastatin
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014